BCLI - Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

• Brainstorm Cell Therapeutics, Inc. is a biotechnology company developing best-in-class autologous cell therapies for treating neurodegenerative diseases including ALS, PMS, Alzheimer's, and others.
• Brainstorm's modified mesenchymal stem cells are being tested in one ongoing Phase 2 trial for PMS (promising top-line data) and one soon-to-be-initiated Phase 2 trial for Alzheimer's.
• Brainstorm is currently deciding how to proceed after their MSC-NTF cell therapy in a Phase 3 trial for ALS didn't meet statistical significance in November 2020.
• Brainstorm is in a reasonable financial position with 1.3 years of a runway with cash of $40M and a TTM cash burn of -$30M.
• In summary, the author projects Brainstorm Cell Therapeutics, Inc. as a "hold" with a positive outlook.

For further details see: